STAT+: Pharmalittle: FDA authorizes another Covid-19 treatment; judge indicates Purdue reorganization plan can be voted on

Top of the morning to you, and a fine one it is. Clear blue skies and deliciously cool breezes are wafting about the Pharmalot campus, where the official mascot is snoozing happily nearby and we are brewing yet another cup of stimulation. Our choice today is butter pecan, for those keeping track. Meanwhile, there is much to be done. The to-do list grows by the minute, it seems. Perhaps you can relate. On that note, here are a few items of interest to help you start your own journey. Hope all goes well today and, as always, do keep in touch. …

The U.S. Food and Drug Administration authorized a monoclonal antibody drug made by Vir Biotechnology (VIR) and GlaxoSmithKline (GSK) to treat early Covid-19 infections, The Wall Street Journal notes. The drug, called sotrovimab, is the third antibody medicine authorized to treat patients early in the course of disease who are at high risk of developing severe cases. Vir and Glaxo are betting the world will be fighting Covid-19 for years to come, even if at a much-reduced scale, because of new virus variants and uneven vaccination rates.

Continue to STAT+ to read the full story…